{"prompt": "['Alliance A171601', 'A PHASE II TRIAL ASSESSING THE TOLERABILITY OFPALBOCICLIB IN COMBINATION WITH', 'LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-', 'POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER', 'Eligibility Criteria (See Section 3.2)', 'Required Initial Laboratory Values', 'Estrogen receptor positive nd/orprogesterone receptor (PR) positive,', 'ANC 1500/mm\u00b3', 'HER2 negative metastatic breast cancer See 3.2.1', 'Platelet count: 100,000/mm\u00b3', 'Measurable disease or non-measurable disease See 3.2.2', 'Creatinine: 30 ml/min*', 'Planning to begin palbociclib for metastatic disease. Patients should', 'Totalserum', '< 1.5 ULN (<3 ULN', 'have failed one prior line of endocrine therapy. See 3.2.3', 'bilirubin', \"if Gilbert's disease)\", 'No prior therapy with a CDK inhibitor See 3.2.4', 'AST and/or', '3x ULN (<5.0x', 'Resolution of all acute toxic effects of prior therapy or surgical', 'ALT', 'ULN if liver', 'procedures to CTCAE Grade 1 (except alopecia) or to baseline', 'metastases present)', 'toxicities prior to previous therapy or surgical procedures. See 3.2.5', 'Alkaline', '<2.5xULN(<5x', 'No untreated brain metastases See 3.2.6', 'phosphatase', 'ULN if bone or', 'No known interstitial lung disease. See 3.2.7.', 'liver metastases', 'No secondmalignancies other than non-melanoma skin cancers or', 'present)', 'cervical carcinoma in situ See 3.2.8.', 'Calculated using the Cockcroft-Gault', 'No active infection requiring treatment with antibiotics See 3.2.9.', 'formula', 'Patients mustbe able to swallow and retain oral medication See', '3.2.10.', 'Patient Age:> 70 years See 3.2.11.', 'ECOG Performance Status 0, 1 or 2 See 3.2.12.', 'Patients mustbe able to readand comprehend Englis h or Spanish See', '3.2.13', 'Schema', '1 cycle = 28 days', 'Treatment:', 'Palbociclib 125 mg a day (Once daily orally', 'Registration', 'on days 1-21 of each 28-day cycle) and', 'Letrozole or Fulvestrant', '(Per treating investigator discretion)', 'Dosing per packet insert in each 28-day', 'cycle', 'Continue protocol treatment until unacceptable toxicity or disease progression', 'Please refer to the full protocol text for a complete description of the eligibility criteria and', 'treatment plan.', '4', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', 'TABLE OF CONTENTS', '1.0', 'BACKGROUNI', '7', '1.1', 'Aging and a Decrease in Physiologic Reserve: Rationale for Studying Cancer Therapy in', 'Older Adults', '7', '1.2', 'Factors Other than Chronological Age that Impact Drug Tolerance', '7', '1.3', 'Palbociclib', '8', '1.4', 'A Rationale for Combining Palbociclib and Endocrine Therapy', '8', '1.5', 'Measurement of Sarcopenia', '11', '1.6', 'Quality of Life Questionnaires: EuroQol 5D 3L and EQ Visual Analog Scale (EQ VAS)', '12', '1.7', 'PRO-CTCAE', '12', '2.0', 'OBJECTIVES', '13', '2.1', 'Primary Objective', '13', '2.2', 'Secondary objectives', '13', '2.3', 'Correlative science objectives', '13', '3.0', 'PATIENTS SELECTION.', '15', '3.1', 'On-Study Guidelines', '15', '3.2', 'Eligibility Criteria', '16', '4.0', 'PATIENTREGIS TRATION.', '17', '4.1', 'Investigator and Research Associate Registration with CTEP', '17', '4.2', 'CTSU Registration Procedures', '18', '4.3', 'Patient Registration Requirements', '20', '4.4', 'Patient Registration/Randomization Procedures', '20', '4.5', 'Registration to Correlative and Companion Studies', '21', '4.6', 'Grouping Factor', '22', '5.0', 'STUDY CALENDAR', '23', '6.0', 'DATA AND SPECIMEN SUBMISSION', '24', '6.1', 'Data Collection and Submission', '24', '6.2', 'Specimen collection and submission', '26', '6.3', 'Digital Image Submission Using TRIAD', '29', '7.0', 'TREATMENTPLAN/INTERVENTION', '31', '7.1', 'Palbociclib', '31', '7.2', 'Letrozole', '32', '7.3', 'Fulvestrant', '32', '7.4', 'Adherence, Geriatric Assessment, and Patient Perspective', '32', '8.0', 'DOSEAND TREATMENT MODIFICATIO NS', '33', '8.1', 'Ancillary Therapy, Concomitant Medications, and Supportive Care', '33', '8.2', 'Dose Modifications', '35', '9.0', 'ADVERSE EVENTS', '36', '9.1', 'Routine Adverse Event Reporting', '36', '9.2', 'CTCAE Routine Reporting Requirements', '37', '9.3', 'Expedited Adverse Event Reporting (CTEP-AERS)', '37', '9.4', 'CAEPR', '42', '10.0', 'DRUG INFORMATION', '45', '10.1', 'General Considerations', '45', '5', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}